New hydroxychloroquine study: Early outpatient treatment is the most effective for treatment of COVID-19 patients, Dr. Harvey A Risch of Yale Univers

More positive news on HCQ.

According to a new study published in American Journal of Epidemiology, early outpatient treatment is the most effective for treatment of coronavirus patients. The study, which was led by Dr. Harvey A Risch of Yale University, suggests that late stage studies missed the point about effective usage of hydroxychloroquine. Dr. Risch says immediate and early ramping-up of treatment for high-risk COVID-19 patients is key to controlling the coronavirus pandemic crisis.

To date, more than 1.6 million Americans have been infected with SARS-CoV-2 and >10 times that number carry antibodies to it. High-risk patients presenting with progressing symptomatic disease have only hospitalization treatment with its high mortality.

According to the abstract of the study, which has not yet been peer-reviewed, Dr. Risch said an outpatient treatment that prevents hospitalization is desperately needed. To date, two candidate medications have been widely discussed: remdesivir, and hydroxychloroquine+azithromycin. “Remdesivir has shown mild effectiveness in hospitalized inpatients, but no trials have been registered in outpatients. Hydroxychloroquine+azithromycin has been widely misrepresented in both clinical reports and public media, and outpatient trials results are not expected until September,” Dr. Harvey A Risch of Yale University, said.

In a 29-page report, the study suggests that early outpatient illness is very different than later hospitalized florid disease and the treatments differ. Evidence about use of hydroxychloroquine alone, or of hydroxychloroquine+azithromycin in inpatients, is irrelevant concerning efficacy of the pair in early high-risk outpatient disease.

Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy. Hydroxychloroquine+azithromycin has been used as standard-of-care in more than 300,000 older adults with multicomorbidities, with estimated proportion diagnosed with cardiac arrhythmias attributable to the medications 47/100,000 users, of which estimated mortality is <20%, 9/100,000 users, compared to the 10,000


In reviewing all available evidence, I will show that HCQ+AZ and HCQ+doxycycline are generally safe for short-term use in the early treatment of most symptomatic high-risk outpatients, where not contraindicated, and that they are
effective in preventing hospitalization for the overwhelming majority of such patients. If these combined medications become standard-of-care, they are likely to save an enormous number of lives that would otherwise be lost to this endemic disease.